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Objective: Real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback
(NF) uses feedback of the patient’s own brain activity to self-regulate brain networks
which in turn could lead to a change in behavior and clinical symptoms. The objective
was to determine the effect of NF and motor training (MOT) alone on motor and non-
motor functions in Parkinson’s Disease (PD) in a 10-week small Phase I randomized
controlled trial.
Methods: Thirty patients with Parkinson’s disease (PD; Hoehn and Yahr I-III) and no
significant comorbidity took part in the trial with random allocation to two groups.
Group 1 (NF: 15 patients) received rt-fMRI-NF with MOT. Group 2 (MOT: 15 patients)
received MOT alone. The primary outcome measure was the Movement Disorder
Society—Unified PD Rating Scale-Motor scale (MDS-UPDRS-MS), administered pre-
and post-intervention “off-medication”. The secondary outcome measures were the
“on-medication” MDS-UPDRS, the PD Questionnaire-39, and quantitative motor
assessments after 4 and 10 weeks.
Results: Patients in the NF group were able to upregulate activity in the supplementary
motor area (SMA) by using motor imagery. They improved by an average of 4.5 points
on the MDS-UPDRS-MS in the “off-medication” state (95% confidence interval: −2.5 to
−6.6), whereas the MOT group improved only by 1.9 points (95% confidence interval
+3.2 to −6.8). The improvement in the intervention group meets the minimal clinically
important difference which is also on par with other non-invasive therapies such as
repetitive Transcranial Magnetic Stimulation (rTMS). However, the improvement did not
differ significantly between the groups. No adverse events were reported in either group.
Interpretation: This Phase I study suggests that NF combined with MOT is safe and
improves motor symptoms immediately after treatment, but larger trials are needed to
explore its superiority over active control conditions.
Keywords: Parkinson’s disease, real-time functional magnetic resonance imaging, neurofeedback, motor
training, WiiFit
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder (de Lau and Breteler, 2006)
affecting the motor circuit and affecting both motor and
non-motor functions. PD currently affects about 5 million
people aged over 50 worldwide and this figure is expected
to rise to approximately 9 million over the next 25 years
(Dorsey et al., 2007) because of increasing life expectancy.
Diagnosis of PD is mainly clinical, although neuroimaging
techniques are used for differential diagnosis (Politis, 2014).
Pharmacotherapy with dopamine precursors (levodopa),
dopaminergic (dopamine receptor agonists, COMT inhibitors,
MAO-B inhibitors) or anticholinergic drugs is the mainstay of
current treatments (Connolly and Lang, 2014) and gives most
patients a considerable amount of motor symptom control.
However, not all motor symptoms respond equally well, and
cognitive decline and motor progression cannot be prevented.
Furthermore, long-term treatment often leads to drug-induced
dyskinesias and behavioral side effects (Hametner et al., 2010;
Beaulieu-Boire and Lang, 2015). Deep-brain stimulation (DBS)
is available as an invasive option to counteract tremor, rigidity
and bradykinesia, but can result in psychiatric, neurological
and surgical complications (Piasecki and Jefferson, 2004;
Fenoy and Simpson, 2014). Various types of motor training
(MOT) therapies and non-invasive brain stimulation are under
development.
Real-time functional magnetic resonance imaging (rt-fMRI)
neurofeedback (NF) has been used to self-regulate brain regions
and modify behavior in healthy individuals and some early
clinical work (review by deCharms, 2008; Caria et al., 2012;
Weiskopf, 2012; Birbaumer et al., 2013). A number of motor
related areas have been successfully modulated using motor
imagery with fMRI NF, primary motor cortex (Yoo and Jolesz,
2002; deCharms et al., 2004; Yoo et al., 2008; Lee et al.,
2009; Chiew et al., 2012), premotor cortex (Johnson et al.,
2012) and supplementary motor cortex (Posse et al., 2001).
Successful modulation of motor areas has also been shown to
modulate functional motor networks (Hui et al., 2014; Xie et al.,
2015).
In our previous proof of concept study (Subramanian
et al., 2011) we compared five patients with PD who
performed motor imagery with fMRI-NF and five patients who
performed motor imagery in the scanner without receiving
feedback. Only the first group showed an increase in activity
in the target area the supplementary motor area (SMA)
and in turn improved their motor functions. This study
provided preliminary evidence that just being in the scanner
environment and performing imagery was not sufficient for
a change in motor functions but that NF was required.
We have now developed an intervention that combines the
concepts of brain stimulation and MOT and mental imagery
practice.
It has been shown that motor imagery leads to activity in
the SMA (Park et al., 2015), which is involved in the initiation
and control of movements, has bidirectional connections with
the basal ganglia (Lindenbach and Bishop, 2013) and has been
reported to be underactive in PD (Nachev et al., 2008). Motor
imagery can also inducemotor cortical plasticity (Avanzino et al.,
2015). Therefore using motor imagery to activate the SMA could
lead to changes in the cortico-basal-ganglia circuit (affected in
PD) inducing plasticity.
Motor imagery has been shown to improve motor
performance, but the effect is short-lived and this may be
due to lack of feedback (Driskell et al., 1994). Therefore by
targeting the SMA and using motor imagery to induce activity in
this area and providing immediate feedback on the performance,
we may be able to produce more lasting changes in motor
circuits, leading to improved motor performance. We therefore
trained patients to upregulate the SMA through NF with fMRI
signals (Subramanian et al., 2011).
Patients had an opportunity to transfer the mental imagery
skills acquired during NF into the real life setting by
practicing the motor imagery at home. Because motor imagery
in combination with physical training has been shown to
improve some motor symptoms in PD patients (Tamir
et al., 2007) we added another transfer technology, using
feedback-based motor exercise on a gaming console (the
Nintendo Wii Fit device). The device when used for exercise
training has been shown to reduce the severity of motor
symptoms in PD patients (Barry et al., 2014). This intervention,
which involved three NF training sessions, regular imagery
homework and six exercise sessions was compared with
a matched control intervention that only involved exercise
on the gaming console in a randomized trial with blinded
assessments.
Our challenge was to design an active control condition that
was not already available as an established treatment protocol.
Our rationale was as follows: the first 4 weeks of intervention
were designed to compare the effect of NF and exercise separately
to see if NF alone was better than exercise alone. As exercise
has previously been shown to have some benefits in alleviating
motor symptoms of PD, in the last 6 weeks of the intervention
we added exercise to the NF training. We expected the NF
training to have an additional benefit but included the exercise
component as a cheaper and more widely available transfer
technology.
MATERIALS AND METHODS
Patients, Eligibility and Randomization
Thirty PD patients (27 males; 3 females) were recruited through
PD specialist physicians and nurses from two NHS health
boards and screened for eligibility at outpatient clinics. Two
additional patients who were recruited and randomized did not
start the intervention because they could not fit it into their
work schedules. Participants received their usual medication
(levodopa, dopamine agonists, amantadine, anticholinergics
or monoamine oxidase B inhibitors), which did not change
over the course of the study. The levodopa equivalent dose
(Table 1) was calculated (Tomlinson et al., 2010) and used
in the randomization procedure (Odekerken et al., 2013; two
levels: above and below 600 mg) along with the age of
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TABLE 1 | Baseline characteristics.
Demographics (all NF group MOT group p-
patients) (N = 15) (N = 15) value
Mean ± SD Mean ± SD
Gender (male/female) 14/1 12/3 -
Hoen and Yahr stage (I/II/III) 7/7/1 5/10/0 -
Age (years) 67 ± 9 63 ± 11 0.6
Time since diagnosis (months) 51 ± 38 57 ± 33 0.6
LEDD 456 ± 219 599 ± 418 0.6
MoCA 26.3 ± 2.5 26.7 ± 1.8 0.6
Included in final analysis: N = 13 N = 13
Primary outcome measure (Off Med)
MDS-UPDRS-MS 23.3 ± 9.4 26.7 ± 12.6 0.9
Secondary outcome measures
(On Med)
MDS-UPDRS-MS 22.9 ± 7.5 21.7 ± 8.0 0.9
MDS-UPDRS-M-DL 13.1 ± 6.9 13.2 ± 7.3 0.9
MDS-UPDRS-NM-DL 9.8 ± 3.9 9.5 ± 4.6 0.9
MDS-UPDRS-SS-DL 49.5 ± 15.6 48.7 ± 18.9 0.9
PDQ-39 19.4 ± 10.4 24.4 ± 15.6 0.9
Quantitative assessments (On Med)
Actigraph (Average steps) 3856 ± 2352 4277 ± 2317 0.9
GaitRite-Walking speed (m/s) 1.1 ± 0.2 1.1 ± 0.2 0.9
GaitRite-Walking cadence 114 ± 9 111 ± 10 0.9
(total steps/min)
GaitRite-Walking step 59 ± 11 60 ± 10 0.9
length left (cm)
GaitRite-Walking step 61 ± 10 60 ± 11 0.9
length right (cm)
NF, neurofeedback; MOT, motor training; SD, standard deviation; N, total
number of patients; LEDD, Levodopa equivalent dose; MoCA, Montreal Cognitive
Assessment scale; Med, medication. P-values are FDR corrected.
the patient (two levels: 65 and above and below 65), to
assist in group matching. Randomization was overseen by the
South East Wales Clinical Trials Unit using the method of
minimization.
Patients were eligible to take part if they had a diagnosis of
PD (according to the UK PD Brain Bank Clinical Diagnostic
Criteria), disease severity within Hoehn and Yahr stages I-III,
no dementia (cut-off score <21/30 on the Montreal Cognitive
Assessment Scale (MoCA; Dalrymple-Alford et al., 2010) or
significant comorbidity and fulfilled the safety requirements for
MRI.
Standard Protocol Approvals,
Registrations and Patient Consents
The study was approved by the South East Wales Research
Ethics Committee, the Cardiff School of Psychology
Ethics Committee, Aneurin Bevan and Cardiff and Vale
Health Boards. All participants gave written informed
consent to participate in the study in accordance with
the Declaration of Helsinki. The trial was registered with
Clinicaltrials.gov (NCT01867827) in May 2013 before
the first patient completed intervention. Enrollment was
between the end of March 2013 and October 2013 and the
last patient completed intervention at the end of January
2014.
Design
This was a small safety and efficacy randomized controlled
trial testing two different interventions (Figure 1: CONSORT
diagram). Group 1 (NF) received rt-fMRI-NF (three sessions: at
the start of the intervention in week 2 (PRE; session 1), week 6
(session 2) and at the end of the intervention in week 12 (POST;
session 3) and regular homework employing mental imagery
for the first 4 weeks of intervention followed by 6 weeks of
supervised MOT with a virtual reality gaming device (Nintendo
Wii) during the rest of the intervention period. Group 2 (MOT)
received supervised MOT on the gaming device throughout the
full intervention period of 10 weeks. No changes were made to
the protocol once the trial had commenced. The study procedure
is summarized in Figure 2.
The sample size of 15 in each group who started the
intervention is similar to randomized controlled trials in PD with
intense exercise therapy (Uhrbrand et al., 2015) and other rt-
fMRI-NF studies (Linden et al., 2012). We wished to document
safety and efficacy of the interventions and to calculate indices
of patient adherence and attrition. Furthermore, we wished to
estimate the sample size for a full powered random, controlled
trial testing the potential benefit of rt-fMRI-NF over and above
MOT without NF.
Primary Clinical Outcome Measure
The motor examination of the MDS-UPDRS (Goetz et al.,
2008) was used as the primary clinical outcome measure and
administered PRE and POST intervention when patients were
in their ‘‘off medication’’ state and also videotaped for later
evaluation. Patients were requested not to take their medication
for 12 h before assessment. The examination was carried out by
two raters (authors LS andDEL), and the inter-rater reliability for
each item was high with an inter-class correlation of 0.94 (pre-
assessment) and 0.92 (post-assessment). Scores provided by the
blind rater (DEL) were used in the analysis. The off-medication
assessments were done 1 week before (Pre) and 1 week after
(Post) the intervention, generally as part of home visits that also
entailed setting up/collecting the actigraphy equipment.
Secondary Outcome Measures
Patients were tested on these measures at three time points (PRE
intervention, after 4 weeks intervention and POST intervention
at 10 weeks) in the ‘‘on medication’’ state.
TheMDS-UPDRS full scale measured non-motor experiences
of daily living (NM-DL), motor experiences of daily living
(M-DL) and motor complications in addition to the motor
examination (motor scale, MS) (which was videotaped for
later evaluation). The Parkinson’s Disease Questionnaire-39
(PDQ-39) measured different aspects of PD and quantitative
motor measures were provided by the Actigraph GT3X and
GaitRite (see Table 1).
The PDQ-39 is self-administered and measures activities
of DL, emotional well-being, stigma, social support, cognitive
impairment, communication and bodily discomfort.
The Actigraph GT3X activity monitor (ActiGraph, LLC,
Pensacola, FL, USA) is a device worn on the waist to measure
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FIGURE 1 | The CONSORT diagram shows the flow of patients through each stage of the randomized, controlled trial.
daily activity levels. The software generates a clinical report of
measures such as number of steps taken during the time the
device was worn, the lifestyle, how sedentary or vigorous the
participant was and how much energy was expended. Wetten
et al. (2014), show that the Actigraph is a valid tool for
quantifying energy expenditure during light intensity stepping.
The number of steps taken was compared between the PRE- and
POST-intervention assessments, when the device was worn for a
week during each assessment.
Changes in gait patterns were measured with the GaitRite
(CIR Systems/GAITRiter, CIR Systems Inc., Franklin, NJ,
USA). This electronic gait analysis system uses a carpet with
sensor pads on it to measure quantitative kinematic parameters
of gait such as speed, number of steps and step length.
Patients were required to walk five times up and down the
carpet to obtain their gait measures at each of the three
assessment sessions in weeks 2, 6 and 12. Data was automatically
generated by the GaitRite software and comparison between
the two groups was performed using the SPSS statistical
package.
We also looked at attrition rate (Figure 1), adherence
to the protocol and adverse events. An acceptable attrition
rate, based on similar complex interventions, would be
25% (Stack et al., 2012). Because of the relatively unique
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FIGURE 2 | Flowchart of the study design with details of the
interventions.
nature of our homework design there were no benchmarking
figures, but we would assume protocol adherence of at
least 75% to be required for successful transfer of learnt
skills into everyday settings based on existing literature
(Hlavaty et al., 2011). Adverse events were defined as any
subjective complaints of physical or mental deterioration or
any physical or psychological impairment requiring medical
intervention.
Screening before Exercise Sessions
All patients filled in the Physical Activity Readiness
Questionnaire PAR-Q before starting the exercise sessions
in order to determine the safety to carry out physical
exercise. In addition their blood pressure and heart
rate were measured before each exercise session which
went ahead only if the values were within the normal
range.
NF Group: Neurofeedback Protocol
Each NF scanning session consisted of a localizer run and four
NF runs, with the exception that in session 3 the fourth run
was a transfer run to see if patients were able to achieve reliable
upregulation without feedback. The localizer run allowed us to
identify the target area (SMA). Activity in this area was then used
to give feedback to the patients during the NF runs.
During the localizer run participants were presented with
an image of a thermometer (with 10 levels) in the center of
a colored background. They were required to execute a motor
task involving sequentially pressing their thumb to each of the
other fingers for 20 s when the background was green and rest
for 20 s when the background turned yellow. The run had
nine cycles of four motor execution and five rest and lasted
3 min.
This simple motor task has been shown to reliably activate
motor networks (Gordon et al., 1998), including the SMA that we
aimed to target (Gerloff et al., 1997). We computed movement
related activation maps online using the TurboBrainVoyager
software package in real-time.
The localizer run was followed by four NF runs (3 min
each). The procedure is similar to the motor execution localizer
run in terms of timing but here, instead of moving their
digits, the patients had to increase activity in the target area
through motor imagery only. They received continuous feedback
about the level of activation through the thermometer display,
which was controlled by their own brain activity in the SMA
target area through a brain computer interface that coupled
the output of the rt-fMRI analysis with the control of the
stimulus display. As activity in the SMA target area increases,
the bars of the thermometer filled with red. Patients were
informed that they might be able to increase activity in the
SMA through motor imagery, but were free to use any specific
imagery strategy. We did not prescribe a particular imagery
strategy, because we considered the adaptive development of
the optimal imagery strategy to be one of the key components
of NF.
In the first 4 weeks of the intervention, patients in the NF
group were asked to practise motor imagery (strategies they had
used during NF) at home for 10 min every day and keep a
record. After the first 4 weeks, they carried on with the imagery
homework and in addition came in once a week for 25 min of
MOT on the Nintendo Wii.
fMRI: Data Acquisition
Functional and anatomical scans were performed in a
3 Tesla GE (General Electric) MRI scanner at the Cardiff
University Brain Research Imaging Centre. A high-resolution
T1-weighted anatomical scan (178 slices) covering the whole
brain was acquired using a fast spoiled gradient-recalled-echo
(FSPGR) pulse sequence. Functional data was obtained using
a single-shot EPI sequence (TR, 2 s; TE, 35 ms; 30 slices;
3 mm thick; flip angle, 80◦). The first six volumes were
discarded to allow for T1 equilibration effects. A total of
100 volumes were acquired in each functional run for each
participant. Scans were acquired in the ascending order and
interleaved.
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TABLE 2 | Changes from baseline to after intervention within and between groups.
NF group ∆ Mean ± SD P (ES) MOT group ∆ Mean ± SD P (ES) ANCOVA (∆NF vs. ∆MOT) p
Primary outcome measure (Off Med)
MDS-UPDRS-MS −4.5 ± 3.3 0.00 (0.8) −1.8 ± 8.3 0.48 0.73
Secondary outcome measures (On Med)
MDS-UPDRS-MS −4.9 ± 3.8 0.000 (0.8) −5.4 ± 4.9 0.02 (0.8) 0.86
MDS-UPDRS-M-DL −1.7 ± 2.3 0.04 (0.6) −1.5 ± 2.8 0.24 0.86
MDS-UPDRS-NM-DL −2.8 ± 2.9 0.01 (0.7) −0.9 ± 3.9 0.48 0.73
MDS-UPDRS-SS −9.2 ± 9.7 0.01 (0.7) −7.9 ± 8.4 0.02 (0.7) 0.86
PDQ-39 −2.4 ± 4.8 0.16 −3.6 ± 6.5 0.24 0.93
Quantitative assessments
Actigraph (Average steps) 487 ± 1270 0.29 252 ± 928 0.48 0.86
GaitRite-Walking speed 0 ± 0 0.88 0 ± 0 0.39 0.81
GaitRite-Walking cadence 0 ± 7 0.88 1 ± 7 0.66 0.86
GaitRite-Walking step length left 0 ± 4 0.88 2 ± 6 0.39 0.81
GaitRite-Walking step length right −1 ± 4 0.78 2 ± 6 0.39 0.73
NF, neurofeedback; MOT, motor training; SD, standard deviation; ES, effect size; Med, medication. P-values are FDR corrected.
Cameras
Four Qualisys Cameras situated in the MR suite were used
to monitor any tremors in the hands. Two markers were
positioned on the tremor dominant hand/dominant hand of
the patients to measure any change in movement during the
NF runs. The movement of the markers was captured 120
times every second and the raw data (movement of the hand
in millimetres) was extracted for each run separately. The
data frequency was reduced to blocks of 20 s allowing us to
differentiate between the resting and imagery periods of the
run. The data points were then subtracted from the baseline
(starting position of the hand) to obtain an indication of
how much the hand had moved. Because of time constraints
this information was only available for eight sessions. The
average movement during the resting and imagery conditions
in the NF runs was negligible (Resting = 0.28 mm and
Imagery= 0.35 mm).
MOT Group: Motor Training
Patients in this group carried out a simple MOT programme on
the Nintendo Wii for three separate sessions in week 2, 6 and 12.
The task was to step on and off the balance board and sideways
following the pattern on the computer screen, and continuous
performance feedback was provided by an avatar.
In the first 4 weeks patients also came into the laboratory
three times a week for 25 min of MOT on the gaming device.
After the first 4 weeks, they continued with the MOT, but now
only once a week for 6 weeks.
Both Groups
Details of Motor Training
During the weekly training sessions in weeks 6–12, the motor
task was to step on and off the virtual reality gaming device
balance board keeping in time to a metronome or following
an avatar on the screen. Each session consisted of two 10 min
blocks and one 5 min block, interleaved with rest periods.
Patients could also pause and rest at any time during the
training.
Both groups were matched for intervention time in the first
month (∼5 h) and for contact time in the following 6 weeks
(3 h). In addition to this the NF group had 10 min of daily motor
imagery practise at home.
Participants in both groups underwent a half hour scan
session before and after the intervention with resting state fMRI,
diffusion tensor imaging and fMRI during a simple motor task
(results from these scans are not reported here). Therefore all
patients who took part in the study were suitable and experienced
being in a scanner environment.
Statistical Analysis
The primary and secondary outcome measures were analyzed
using the SPSS statistical package (version 20).
An independent samples t-test was performed on all the
measures to determine any difference between the groups at
baseline (Table 1).
A paired samples t-test was carried out to determine
changes in the outcome measures from PRE to POST
intervention within each group. We also performed analysis
of covariance (ANCOVA) on all the measures at POST
intervention with the PRE intervention score as the covariate
to test for any significant difference between the groups
(Table 2).
A repeated measures analysis of variance (ANOVA) with
time (sessions 1, 2, 3) as within subject and group (NF vs.
MOT) as between subject factors on the secondary outcome
measures was also performed to test for time-dependent changes
in variables and interaction between time and group factors
(Table 3). Multiple comparisons of tests was accounted for by
adjusting the false discovery rate (FDR) using the ‘‘R’’ statistical
package (version 3.2.4).
fMRI Data Analysis (On-Line)
Data from the motor execution localizer and motor imagery
NF runs were obtained from the scanner and analyzed online
on an analysis computer (Johnston et al., 2010) before being
fed back to the participant in the scanner. The real-time
fMRI software package, TurboBrainVoyager version 3.2 (TBV,
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TABLE 3 | ANOVAs for clinical secondary outcome measures “on-medication” across all three time assessments.
ANOVA
Measures Effect of time Effect of group Time × Group interaction effect
MDS-UPDRS-MS F(2,48) = 8.36, p = 0.002 (ES = 0.26) F(1,24) = 0.15, p = 0.7 (N/S) F(2,48) = 3.51, p = 0.03 (ES = 0.13)
MDS-UPDRS-SS F(2,48) = 13.46, p = 0.000 (ES = 0.36) F(1,24) = 0.32, p = 0.7 (N/S) F(2,48) = 7.64, p = 0.005 (ES = 0.24)
MDS-UPDRS-M-DL F(2,48) = 4.34, p = 0.01 (ES = 0.15) F(1,24) = 0.22, p = 0.7 (N/S) F(2,48) = 5.58, p = 0.01 (ES = 0.19)
MDS-UPDRS-NM-DL F(2,48) = 4.98, p = 0.01 (ES = 0.17) F(1,24) = 0.55, p = 0.7 (N/S) F(2,48) = 2.14, p = 0.13, (N/S)
PDQ-39 F(2,48) = 4.46, p = 0.02 (ES = 0.16) F(1,24) = 1.91, p = 0.7 (N/S) F(2,48) = 3.79, p = 0.03 (ES = 0.14)
ANOVA, Analysis of variance; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; MS, motor subscale; SS, summed score; M-DL,
Motor aspects of daily living; NM-DL, non motor aspects of daily living; PDQ, Parkinson’s disease questionnaire; ES, effect size; N/S, not significant; P-values are FDR
corrected.
Brain Innovation) was used. Data was read volume by volume,
corrected for angular and translational motion and analyzed
with an incremental general linear model (GLM). For the motor
execution localizer run, we used one predictor for the movement
blocks (convolved with a canonical hemodynamic response
function) to identify areas of movement-related activation.
The t-value for the contrast between movement and rest in
the localizer map was set at 3. We took the peak midline
activation from the SMA during the motor execution localizer
run as the target area for the NF runs. The region of
interest was selected by choosing the whole of the extent in
the x–y plane (on the axial slice) encompassing the activity
in the SMA with an extent across three slices in the z
direction.
In the NF runs, the ‘‘thermometer’’ displayed the percentage
signal change to patients (with a full thermometer denoting
1% signal change, which is around the maximum of what
patients could achieve) from baseline computed for the top
third of most active voxels of the region of interest for
an average of three time points. The baseline value was
set to the average signal intensity value recorded from the
last three time points during the preceding ‘‘fixation’’ period
to the current upregulation block. Patients were informed
of the approximate 5 s time lag between a change in
neural activity and its reflection in the blood-oxygen-level
dependent signal (and thus on the feedback display). The
stimulation interface was custom programmed in PsychoPy
(Peirce, 2007) and presented from a Macintosh computer. This
interface allows updating of feedback within ∼1 s of data
acquisition.
fMRI Data Analysis (Off-Line)
We conducted further off-line fMRI analyses to ascertain
whether participants reliably upregulated the target
area (region-of-interest [ROI] analysis) and whether
activation patterns changed as a result of the NF
intervention in other parts of the brain (whole brain
analysis).
fMRI data were preprocessed using the BrainVoyager QX
software package (version 2.6; Brain Innovation, Maastricht,
Netherlands). Data for each subject was analyzed using a GLM
with one predictor for the ‘‘motor execution’’ condition in the
localizer and a single predictor for ‘‘upregulation’’ during the
motor imagery NF runs. The regressors for both were convolved
with a canonical hemodynamic reference function accounting for
the temporal delay and dispersion of the hemodynamic response.
Six motion confounds and two for heart rate and respiration
were added to the GLM for each of the runs. The models
were used for both ROI and whole brain random effects group
analysis.
Motion correction and temporal filtering were performed
on the raw data to remove artifacts due to head movement and
physiological noise. The functional data were then co-registered
to the T1 anatomical scan and transformed into Talairach
coordinate space (Talairach and Tournoux, 1998). Spatial
smoothing with a Gaussian filter (full width at half maximum
(FWHM) of 6 mm) was applied to the volume time course
files.
For the ROI analysis we extracted the beta and t-values
for the ‘‘upregulation’’ predictor from the SMA target area for
each run and subjected them to a repeated measures ANOVA
with the within-subject factor of session. We performed a
correlation analysis (Pearson’s r) between the improvement
of the MDS-UPDRS clinical scores (Pre-Post) and the overall
NF success (measured in average t-value across the three
sessions).
For the whole brain analysis an average of the participant’s
anatomical scans was created and used in the analysis. A whole
brain mask was also created to restrict the number of voxels used.
We used the cluster-level correction approach implemented
in the Brainvoyager software (1000 iterations) to control for
multiple comparisons across the brain (cluster-level corrected
threshold: p< 0.05).
Whole Brain Analysis
We conducted a random effects analysis in Brain Voyager,
for activation during the upregulation sessions in the
10 participants with full data sets (2 sessions with 4 runs
each and 1 session with 3 runs; transfer run was excluded)
corrected for multiple comparisons across the brain with cluster
level correction.
RESULTS
Sample Characteristics
Data were approximately normally distributed. Shapiro-
Wilk’s test was non-significant (p > 0.05) for all measures
except the scores of the MDS-UPDRS MS ‘‘on medication’’
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FIGURE 3 | (A) “Off- medication” PRE- and POST-intervention mean scores of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) motor subscale (MS) for both groups with higher scores indicating greater impairment; (B) “On-medication” mean scores of the MDS-UPDRS MS for
the three assessment sessions for both groups with higher scores indicating greater impairment; (C) “On-medication” mean scores of the non-motor experience of
daily living (NM-DL) sub scale of the MDS-UPDRS for the three assessment sessions for both groups; (D) “On-medication” mean scores of the motor-experience of
daily living sub scale of the MDS-UPDRS for the three assessment sessions for both groups. ∗ indicates significant difference.
(MOT group) sessions 2 and 3 and MDS-UPDRS NM-
DL (NF group) session 1. For these measures visual
inspection of Q-Q plots confirmed approximately normal
distribution.
Primary Outcome Measure: PRE- vs.
POST-Intervention
The ANCOVA analysis revealed no statistically significant
difference between the effects of the intervention in the
NF vs. MOT groups (F(1,23) = 2.62; p = 0.11; Table 2).
Participants in the NF group improved on average by
−4.5 points on the MDS-UPDRS-MS-off-medication
(95% confidence interval −2.5 to −6.6), whereas those
in the MOT group only tended to improve by −1.9
points (confidence interval +3.2 to −6.8; see Table 2 and
Figure 3A).
Secondary Outcome Measures: PRE- vs.
POST-Intervention
The ANCOVA’s showed no significant difference between the
groups in any of the measures (Table 2). Results of the paired
samples t-test and ANCOVAs on all the clinical and quantitative
measures are reported in Table 2.
Time-Dependent Changes in Secondary
Clinical Measures During the Interventions
Results of the ANOVAs on the ‘‘on-medication’’ clinical
measures acquired at the three assessment time points are
reported in Table 3. Of these, the MDS-UPDRS-MS, MDS-
UPDRS-SS, MDS-UPDRS-M-DL and PDQ-39 showed a
significant interaction term for time × group analysis, driven by
faster improvements in the NF group. Two of the time × group
interactions (on MDS-UPDRS-SS and MDS-UPDRS-M-DL)
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FIGURE 4 | (A) Mean beta values from the neurofeedback (NF) scans for the
three different sessions in weeks 2, 6 and 12 of the NF intervention. Bars are
standard errors; (B) Areas of significant activation across all NF sessions
(whole brain based analysis). (C) Sagittal view of the brain showing a
probabilistic map of the overlap across regions of interest (ROI’s)
supplementary motor area (SMA) used for NF training across patients. PM,
probabilistic map.
survived Bonferroni correction for multiple testing (across
the five clinical secondary outcome measures) at a corrected
p-value<0.05.
Adherence
Twenty six of the 30 patients who underwent the interventions
completed the study, which yields an attrition rate of 13%
(Figure 2). Patients in the NF group adhered to the imagery
homework (11 of 13 patients returned the diaries at the end of
the study), with a 75% rate of completed homework (calculated
as daily entries). For theMOT group, the adherence rate was 84%.
No adverse events were reported in either group.
Functional Magnetic Resonance Imaging
Analysis: ROI Analysis
Patients in the NF group were able to upregulate the SMA during
the NF sessions. Successful upregulation was defined as a positive
‘‘t’’ or ‘‘beta’’ value for the upregulation vs. baseline contrast from
the brain voyager analysis.
Using SPSS we computed a one way repeated measures
ANOVA with session as a factor. There was no significant
increase in SMA activation across sessions (betas: F(2,24) = 1.34;
p = 0.28; Figure 4A; t-values: F(2,24) = 1.19; p = 0.31), but
there was a significant difference of the means from zero as
seen from the intercept (betas: F(1,12) = 21.60; p = 0.001;
t-values: F(1,12) = 20.47; p = 0.001), indicating successful SMA
upregulation from baseline activity.
We found a trend-level correlation [r = −0.448, p = 0.06
(1-tailed)] between the improvement of the MDS-UPDRS
clinical scores and the overall NF success.
Patients were able to upregulate the SMA without any change
in voluntary or involuntary hand movements as measured using
the camera system.
Whole Brain Analysis
The whole brain analysis of activation during SMA upregulation
blocks across all sessions revealed additional significant activity
compared to baseline in the subthalamic nucleus, cerebellum,
frontal areas, insula, putamen and anterior cingulate (Table 4 and
Figure 4B).
DISCUSSION
We showed that a new intervention for PD that combines
fMRI-based NF with mental imagery and MOT was safe and
brought improvement of motor symptoms. The NF group
showed an improvement of −4.5 points (−20%) on the primary
clinical outcomemeasure of the ‘‘off-medication’’ MDS-UPDRS-
MS. We used the off medication state motor assessment as
the primary outcome measure because non-pharmacological
interventions that promote compensation may operate through
non-dopaminergic mechanisms (Bezard et al., 2003), and thus
difference is most prominent in the off medication state.
This clinical improvement was in the range of the minimal
clinically important difference (−5 points; Schrag et al., 2006;
Shulman et al., 2010) and similar to that seen in the NF
group of our pilot study (Subramanian et al., 2011). It is also
similar to that commonly achieved by adding a second drug
to a dopamine agonist (decrease of up to 5 points on the
UPDRS motor scale (MS); Pinter et al., 1999; Stocchi et al.,
2004) and to that reported in a meta-analysis of transcranial
magnetic stimulation (TMS) studies (pooled mean difference
of −6 points on the UPDRS motor scale; Fregni et al.,
2005).
Electroencephalography (EEG) based NF has been studied in
PD patients with inconsistent findings and various limitations
(Esmail and Linden, 2014). With fMRI based NF showing
promising outcomes, transferring this learning to EEG
NF could further maintain successful motor imagery (Bai
et al., 2014) and induce brain changes (Ros et al., 2010)
outside the scanner as this would be more cost effective in
the long term. Recent studies have shown the possibility
of identifying cortical signatures (Zich et al., 2015) and
developing fMRI based EEG fingerprints for sub-cortical brain
areas (Keynan et al., 2016) with simultaneous fMRI-EEG
acquisition.
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TABLE 4 | Brain areas activated and deactivated during the NF runs from all sessions.
Clusters of brain areas activated Peak x/y/z t-value p-value Cluster size (mm3)
Supplementary motor area −7/1/57 7.98 0.000022 7434
Cingulate gyrus 5/7/27 3.62 0.005538 1678
Right insula 29/28/6 3.84 0.003911 4013
Left putamen −28/−5/3 2.61 0.028177 200
Right globus pallidus 12/−7/−3 3.39 0.007986 257
Left globus pallidus −16/−8/−3 3.16 0.011523 335
Right subthalamic nucleus 11/−11/−3 3.98 0.003186 650
Left subthalamic nucleus −13/−11/−3 3.22 0.010461 423
Midbrain −1/−17/−9 3.77 0.004388 1220
Cerebellum 35/−53/−24 7.68 0.000030 5166
Right parietal cortex 48/−62/30 −5.08 0.000659 4540
Left occipital cortex −28/−86/−6 −5.30 0.000489 2453
Right occipital cortex 32/−83/0 −3.97 0.003215 628
The intervention had a relatively high intensity in both
groups and resulted in a clinically significant improvement in
the NF group. However, the ANCOVA showed no significant
group difference in the primary outcome measure or in the
secondary clinical outcome measures of motor and non-motor
functions or in the quantitative measures. Thus, we did not
demonstrate statistical superiority for the NF compared to the
MOT intervention, perhaps because MOT interventions can
have therapeutic benefits in their own right (Barry et al., 2014;
Shen and Mak, 2015). However, the present study can provide
power estimates for future studies addressing the difference in
efficacy between NF and active control interventions. Using the
data from this pilot study to estimate the common standard
deviation (SD) of 13 points for the MDS-UPDRS measure (the
highest of the group SDs and therefore the most conservative)
and setting the minimal clinically important difference as −5
points, for a power of 80% a two tailed Student’s t-test (α= 0.05)
gives a required sample size of 101 per group in a two group
comparison.
Although the secondary clinical outcome measures were
similar across the two intervention groups at the POST-
intervention assessment, the improvement may have occurred at
an earlier stage of the intervention period (already at assessment
time point 2) in the NF group (Figures 3B–D; statistics Table 3),
as indicated by the significant group× time interaction forMDS-
UPDRS-SS and MDS-UPDRS-M-DL. One explanation could be
that motor skill acquisition was accelerated in the NF group,
but further mechanistic studies would be needed to confirm
this.
Only the NF group showed significant improvement on the
‘‘off-medication’’ UPDRS-MS, whereas both groups improved
on the ‘‘on-medication’’ MDS-UPDRS-MS assessment. One
possible reason might be that NF training leads to restitution
of some aspects of basal ganglia (BG) function, which may
confer benefits even in the absence of externally enhanced
dopaminergic activity. However, because the majority of patients
for whom NF is considered will likely be and remain on
medication, motor assessment during the ‘‘on medication’’
state should be included as a primary outcome in future
trials.
Although the correlation between the improvement of
the MDS-UPDRS clinical scores and the overall NF success
was not significant due to the small sample size, the
association goes in the expected direction (the MDS-UPDRS
clinical score and t-values are negatively correlated, thus
improvement in the clinical scores was associated with higher
activation of the target area). This preliminary indication of an
association between the intervention and clinical improvement
corroborates the need for larger, sufficiently powered studies of
NF in PD.
The whole-brain imaging analysis suggested some
mechanisms through which self-regulation training of the
SMA may influence brain networks relevant in PD. During
NF, we observed co-activation of other cortical motor areas
and subcortical areas, including the subthalamic nucleus and
putamen. This may suggest that self-regulation training of
higher cortical motor areas can indeed modulate the subcortical
loops implicated in PD, although more detailed analysis of NF
imaging data, including functional connectivity analysis (Rota
et al., 2011; Scharnowski et al., 2014) will be needed to probe any
neuroplastic changes.
Limitations
Our study did not have a control group in the scanner receiving
sham feedback or any other control feedback. rtfMRI NF has
been tested in other clinical applications such as chronic pain,
tinnitus, stroke, depression, schizophrenia, obesity and addiction
with some preliminary promising results with various control
conditions and it is recognized that no single control condition
can address all the mechanisms that may underlie clinical
improvement under NF (Sulzer et al., 2013). We did not use
sham feedback as this may frustrate patients and artificially
induce superior effects in the real NF group. Instead we
used an active control group with feedback based physical
intervention, which was matched with the NF intervention for
intensity.
With regard to the imagery strategy used by the patients,
we did not prescribe a particular imagery strategy, because we
considered the adaptive development of the optimal imagery
strategy to be one of the key components of NF. Future studies
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could explore separately the effect of visual and kinesthetic
motor imagery and differentiate between upper and lower limb
imagery.
Because we did not demonstrate statistical superiority for
the NF over MOT intervention in our sample one might query
whether relatively expensive, laboratory-based interventions
should be pursued, as compared to, for example, physiotherapy.
However, in a recently completed randomized controlled trial
of PD rehabilitation (Clarke et al., 2014) a combination of
occupational therapy and physiotherapy was not found to be
better than no therapy. Similarly, the MOT group in our study
showed no relevant clinical improvement. Thus, there is a case
for larger studies of NF-based interventions that will explore
whether this technique can provide the crucial boost to other
training-based interventions that leads to lasting clinical and
functional improvements.
CONCLUSION
rt-fMRI-NF is a new safe technique for self-regulation of motor
networks in PD with good feasibility and patient adherence
and preliminary evidence for short-term efficacy. However,
further studies are needed to demonstrate its efficacy as an
add-on treatment and superiority over other interventions.
Inclusion of follow-up assessments would track the long-term
retention of clinical improvements and enable the assessment of
the cost-effectiveness of the NF intervention. Future trials may
also help to identify neuro-imaging biomarkers for prediction of
successful application of NF in individual PD patients.
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